Fulvestrant + Neratinib In Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Stage IV (Metastatic) Breast Cancer|Metastatic Breast Cancer|ER Positive Breast Cancer|PR-Positive Breast Cancer|HER2-negative Breast Cancer|Invasive Breast Cancer
Interventions: DRUG: NERATINIB|DRUG: FULVESTRANT
Sponsor: Massachusetts General Hospital
Collaborators: Celcuity Inc|Puma Biotechnology, Inc.